Current and novel therapeutic options for irritable bowel syndrome management

M. Camilleri, V. Andresen

Research output: Contribution to journalShort surveypeer-review

44 Scopus citations


Irritable bowel syndrome is a functional gastrointestinal disorder affecting up to 3-15% of the general population in western countries. It is characterised by unexplained abdominal pain, discomfort, and bloating in association with altered bowel habits. The pathophysiology of irritable bowel syndrome is multifactorial involving disturbances of the brain-gut axis. The pathophysiology provides the rationale for pharmacotherapy: abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, autonomic dysfunction, and mucosal immune activation. Understanding the mechanisms, and their mediators or modulators including neurotransmitters and receptors have led to several therapeutic approaches including agents acting on the serotonin receptor or serotonin transporter system, antidepressants, novel selective anticholinergics, α-adrenergic agonists, opioid agents, cholecystokinin-antagonists, neurokinin-antagonists, somatostatin receptor agonists, corticotropin releasing factor antagonists, chloride channel activators, guanylate cyclase-c agonists, melatonin, atypical benzodiazepines, antibiotics, immune modulators and probiotics. The mechanisms and current evidence regarding efficacy of these agents are reviewed.

Original languageEnglish (US)
Pages (from-to)854-862
Number of pages9
JournalDigestive and Liver Disease
Issue number12
StatePublished - Dec 2009


  • Clinical trials
  • Opioids
  • Pharmacodynamics
  • Pharmacology
  • Serotonergics

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Current and novel therapeutic options for irritable bowel syndrome management'. Together they form a unique fingerprint.

Cite this